[Radiotherapy in localized stages of follicular and diffuse non-Hodgkin's lymphomas].
Treatment with monoclonal antibodies, especially rituximab, is more and more frequent and questions the interest of radiotherapy in limited stages of diffuse B-cell large cell and follicular non-Hodgkin's lymphomas. From a review of literature, it appears that radiotherapy is of interest in bulky disease, patients with incomplete metabolic response, elderly patients receiving short chemotherapy and those with recurrence after exclusive chemotherapy. Finally, this article gives recommendations on available techniques of radiotherapy and doses to be delivered.
Inserm, UMRS 1018, institut Gustave-Roussy, 114, rue Edouard-Vaillant, 94805 Villejuif, France.
C
C
Demoor-Goldschmidt
Département d'oncologie médicale, institut de cancérologie de l'Ouest-René-Gauducheau, boulevard Jacques-Monod, 44800 Saint-Herblain, France.
P
P
Agape
Centre universitaire de cancérologie Henry-s-Kaplan, CHU, 37000 Tours, France.
I
I
Barillot
Département de radiothérapie, institut de cancérologie de l'Ouest-René-Gauducheau, boulevard Jacques-Monod, 44800 Saint-Herblain, France. Electronic address: marc-andre.mahe@ico.unicancer.fr.
M A
MA
Mahé
D000970:Antineoplastic Agents / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000473:pathology / Q000628:therapy*; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant
D000970:Antineoplastic Agents
Diffuse B-cell lymphomas; Follicular lymphomas; Lymphomes B diffuse à grandes cellules; Lymphomes folliculaires; Lymphomes non hodgkiniens; Non-Hodgkin's lymphomas; Radiotherapy; Radiothérapie; Rituximab